Quarterly ResultAug 7, 2026, 04:14 PM
aTyr Pharma Q2 Net Loss Per Share $(0.11); Kyorin Agreement Terminated
AI Summary
aTyr Pharma reported a consolidated net loss of $10.3 million, or $(0.11) per share, for Q2 2026, a significant improvement from the prior year. Research and development expenses decreased to $6.7 million. The company also announced the termination of its collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd., effective July 30, 2026, with all rights for efzofitimod in Japan reverting to aTyr Pharma. The company believes its $58.9 million in cash and investments will fund operations for at least one year.
Key Highlights
- Q2 2026 net loss attributable to aTyr Pharma was $(10.3) million.
- Q2 2026 net loss per share was $(0.11), an improvement from $(0.22) in Q2 2025.
- Research and development expenses decreased to $6.7 million in Q2 2026.
- Kyorin Agreement for efzofitimod in Japan was terminated, rights reverted.
- Total cash, cash equivalents, and investments were $58.9 million as of June 30, 2026.
- Net cash used in operating activities was $(21.9) million for YTD 2026.
- Company believes current capital is sufficient for at least one year.
- Securities class action lawsuit ongoing; motion to dismiss filed.
Price Impact
More from ATYR